Work

A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.4131

Authors: Timothy J Brown, Mark H. O'Hara, Ursina R. Teitelbaum, Thomas Benjamin Karasic, Charles John Schneider, Natallia Izgur, Katherine L. Nathanson, Susan M. Domchek, Kim Anna Reiss

Institutions: Hospital of the University of Pennsylvania, Abramson Cancer Center, University of Pennsylvania, University of Pennsylvania Health System

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4281674076

Cites:

Cited by: 2

Related to: 10